GeneDx Holdings(WGS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

WGS GeneDx Holdings

Post-Mkt 02-17 17:49:57 EST

91.03

+0.88

+0.98%

盘后91.03

+0.000.00%

17:01 EST

High92.57	Low86.12	Vol308.34K
Open88.35	D1 Closing90.15	Amplitude7.15%
Mkt Cap2.63B	Tradable Cap1.82B	Total Shares28.90M
T/O27.90M	T/O Rate1.55%	Tradable Shares19.94M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"WGS","market":"US","secType":"STK","nameCN":"GeneDx Holdings","latestPrice":91.03,"timestamp":1771362000000,"preClose":90.15,"halted":0,"volume":308340,"hourTrading":{"tag":"盘后","latestPrice":91.03,"preClose":91.03,"latestTime":"17:01 EST","volume":9054,"amount":824185.402704,"timestamp":1771365693957,"change":0,"changeRate":0,"amplitude":0.000549},"delay":0,"changeRate":0.009761508596783089,"floatShares":19944938,"shares":28904590,"eps":0.073539,"marketStatus":"Post-Mkt","change":0.88,"latestTime":"02-17 17:49:57 EST","open":88.35,"high":92.57,"low":86.12,"amount":27898489.1142,"amplitude":0.071547,"askPrice":92.81,"askSize":21,"bidPrice":90.6,"bidSize":50,"shortable":3,"etf":0,"ttmEps":0.073539,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1771376400000},"marketStatusCode":4,"adr":0,"exchange":"NASDAQ","adjPreClose":90.15,"preHourTrading":{"tag":"盘前","latestPrice":88.33,"preClose":90.15,"latestTime":"09:28 EST","volume":43,"amount":3835.6301,"timestamp":1771338530034,"change":-1.82,"changeRate":-0.020189,"amplitude":0.032834},"postHourTrading":{"tag":"盘后","latestPrice":91.03,"preClose":91.03,"latestTime":"17:01 EST","volume":9054,"amount":824185.402704,"timestamp":1771365693957,"change":0,"changeRate":0,"amplitude":0.000549},"volumeRatio":0.430239,"impliedVol":1.2279,"impliedVolPercentile":0.8287},"requestUrl":"/m/hq/s/WGS/tweets","defaultTab":"tweets","newsList":[{"id":"1108970592","title":"Earning Preview: GeneDx Holdings revenue is expected to increase by 46.43%, and institutional views are mostly bullish","url":"https://stock-news.laohu8.com/highlight/detail?id=1108970592","media":"Earnings Agent","labels":["earningPreview"],"top":1,"itemType":null,"share":"https://ttm.financial/m/news/1108970592?lang=en_us&edition=fundamental","pubTime":"2026-02-16 12:19","pubTimestamp":1771215582,"startTime":"0","endTime":"0","summary":"Abstract GeneDx Holdings will report fourth-quarter 2025 results on February 23, 2026 Pre-Market; expectations center on revenue near $120.41 million and adjusted EPS around $0.11, with investors...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Earning Preview: GeneDx Holdings revenue is expected to increase by 46.43%, and institutional views are mostly bullish","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["WGS"],"gpt_icon":0},{"id":"2610956838","title":"BRIEF-Time Names Genedx CEO Katherine Stueland To The 2026 Time100 Health List Of The World’S Most Influential Leaders In Health","url":"https://stock-news.laohu8.com/highlight/detail?id=2610956838","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610956838?lang=en_us&edition=fundamental","pubTime":"2026-02-11 22:30","pubTimestamp":1770820215,"startTime":"0","endTime":"0","summary":"BRIEF-Time Names Genedx CEO Katherine Stueland To The 2026 Time100 Health List Of The World’S Most Influential Leaders In HealthFeb 11 (Reuters) - GeneDx Holdings Corp WGS.O:TIME NAMES GENEDX CEO KATH","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260211:nTUA9KB2DD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4196","WGS"],"gpt_icon":0},{"id":"2610207953","title":"Time Names GeneDx CEO Katherine Stueland to the 2026 Time100 Health List of the World’s Most Influential Leaders in Health","url":"https://stock-news.laohu8.com/highlight/detail?id=2610207953","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610207953?lang=en_us&edition=fundamental","pubTime":"2026-02-11 22:05","pubTimestamp":1770818700,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260211:nTUA9KB2DD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4196","WGS"],"gpt_icon":0},{"id":"2610630338","title":"Wells Fargo Upgrades GeneDx Holdings to Overweight From Equalweight","url":"https://stock-news.laohu8.com/highlight/detail?id=2610630338","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610630338?lang=en_us&edition=fundamental","pubTime":"2026-02-09 20:21","pubTimestamp":1770639686,"startTime":"0","endTime":"0","summary":"GeneDx Holdings (WGS) has an average rating of buy and mean price target of $170, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major banks ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["WGS"],"gpt_icon":0},{"id":"2610634601","title":"GeneDx Holdings Corp. : Wells Fargo Raises to Overweight From Equal Weight","url":"https://stock-news.laohu8.com/highlight/detail?id=2610634601","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610634601?lang=en_us&edition=fundamental","pubTime":"2026-02-09 19:22","pubTimestamp":1770636168,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260209:nAZN4SFKAR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["WGS","BK4196"],"gpt_icon":0},{"id":"2610181684","title":"U.S. RESEARCH ROUNDUP-Align Technology, Biogen, Citigroup","url":"https://stock-news.laohu8.com/highlight/detail?id=2610181684","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610181684?lang=en_us&edition=fundamental","pubTime":"2026-02-09 15:27","pubTimestamp":1770622069,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-Align Technology, Biogen, Citigroup  Feb 9 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Align T","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260209:nL4N3Z50KK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HBAN","HIMS","CFG","C","AMAT","CENT","HCA","DOCS","LU0109394709.USD","BK4581","FLS","AN","CSCO","BIIB","LU0342679015.USD","BK4076","DDOG","LU1559883803.SGD","BYD","CLSK","BK4585","ALGN","FIVE","BBY","CI","LU2237443549.SGD","FTV","BAC","COST","HUBS","EL","ITW","AVY","ELF","INTU","ATR","HP","CCK","LU0889566641.SGD","SG9999015978.USD","ARES","ENSG","THG","WGS","IE00BFMHRM44.USD","LU1506573853.SGD","CBOE","COTY","CTSH"],"gpt_icon":0},{"id":"2609119385","title":"GeneDx COO Bryan Dechairo Reports Disposal of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2609119385","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609119385?lang=en_us&edition=fundamental","pubTime":"2026-02-07 05:19","pubTimestamp":1770412776,"startTime":"0","endTime":"0","summary":"Bryan Dechairo, Chief Operating Officer, reported a disposal of common shares of GeneDx Holdings Corp. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genedx Holdings Corp. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on February 06, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260206:nNDL9Dv7WP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"GeneDx COO Bryan Dechairo Reports Disposal of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4196","WGS"],"gpt_icon":0},{"id":"2608687939","title":"GeneDx Holdings Corp. to Release Fourth Quarter Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2608687939","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608687939?lang=en_us&edition=fundamental","pubTime":"2026-02-03 21:01","pubTimestamp":1770123712,"startTime":"0","endTime":"0","summary":"GeneDx Holdings Corp.  will release its fourth quarter 2025 financial results before the market opens on Monday, February 23, 2026. Management will host a conference call to discuss the results at 8:30 a.m. Eastern Time. A live and archived webcast of the event will be available in the \"Events\" section of the GeneDx investor relations website at GeneDx investor relations website.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genedx Holdings Corp. published the original content used to generate this news brief via Business Wire  on February 03, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260203:nNDLbS7cvx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["WGS","BK4196"],"gpt_icon":0},{"id":"2608882472","title":"Analysts Are Bullish on Top Healthcare Stocks: Immutep Ltd (PRRUF), GeneDx Holdings (WGS)","url":"https://stock-news.laohu8.com/highlight/detail?id=2608882472","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608882472?lang=en_us&edition=fundamental","pubTime":"2026-02-02 07:10","pubTimestamp":1769987412,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Immutep Ltd (PRRUF – Research Report) and GeneDx Hol...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-immutep-ltd-prruf-genedx-holdings-wgs-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-immutep-ltd-prruf-genedx-holdings-wgs-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","LU0128526141.USD","LU0029874061.USD","BK4196","XBI","BK4585","PRRUF","WGS","BK4139","BK4137","BK4112","BK4581","LABU"],"gpt_icon":0},{"id":"2607092078","title":"Cathie Wood’s ARK Investment buys 91.8K shares of GeneDx today","url":"https://stock-news.laohu8.com/highlight/detail?id=2607092078","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607092078?lang=en_us&edition=fundamental","pubTime":"2026-01-31 09:50","pubTimestamp":1769824219,"startTime":"0","endTime":"0","summary":"20:48 EST Cathie Wood’s ARK Investment buys 91.8K shares of GeneDx (WGS) today Published first on TheFly – the ultimate source for real-time, marke...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/cathie-woods-ark-investment-buys-91-8k-shares-of-genedx-today-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/cathie-woods-ark-investment-buys-91-8k-shares-of-genedx-today-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["WGS","ARKK","BK4196","BK4588","BK4544","BK4585"],"gpt_icon":0},{"id":"2606078079","title":"Myriad Advances MRD Commercialization Timeline, Bolstered by New Study Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2606078079","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606078079?lang=en_us&edition=fundamental","pubTime":"2026-01-27 21:50","pubTimestamp":1769521800,"startTime":"0","endTime":"0","summary":"Precise MRD to transition from research-use-only into a limited clinical launch in March 2026SALT LAKE CITY, Jan.  27, 2026  (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molec","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/01/27/3226525/15459/en/Myriad-Advances-MRD-Commercialization-Timeline-Bolstered-by-New-Study-Data.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4196","WGS","BK4139","MYGN"],"gpt_icon":0},{"id":"2603393795","title":"GeneDx Holdings (WGS) Valuation After Strong 2025 Outlook And New Genomics Growth Initiatives","url":"https://stock-news.laohu8.com/highlight/detail?id=2603393795","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603393795?lang=en_us&edition=fundamental","pubTime":"2026-01-16 04:35","pubTimestamp":1768509307,"startTime":"0","endTime":"0","summary":"GeneDx Holdings (WGS) is back in focus after issuing preliminary 2025 results and fresh 2026 guidance, outlining revenue expectations tied to exome and genome volumes, along with new product launches and data partnerships.\nSee our latest analysis for GeneDx Holdings.\nDespite a sharp 1 day share price return of 4.8% decline and a 30 day share price return of 26.2% decline that suggest sentiment has cooled after the guidance update, the 1 year total shareholder return of 53.2% and a very large...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/9551730-choice2-main-header/1585186975683","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/9551730-choice2-main-header/1585186975683"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nasdaq-wgs/genedx-holdings/news/genedx-holdings-wgs-valuation-after-strong-2025-outlook-and","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/healthcare/nasdaq-wgs/genedx-holdings/news/genedx-holdings-wgs-valuation-after-strong-2025-outlook-and","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4196","WGS"],"gpt_icon":0},{"id":"2603293168","title":"Health Minister Responds to Reports of Two Super Flu Cases in Bali","url":"https://stock-news.laohu8.com/highlight/detail?id=2603293168","media":"Tempo","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603293168?lang=en_us&edition=fundamental","pubTime":"2026-01-15 23:30","pubTimestamp":1768491037,"startTime":"0","endTime":"0","summary":"TEMPO.CO, Jakarta- Health Minister Budi Gunadi Sadikin urged the public not to panic over the discovery of two cases of influenza A  subclade K, also known as \"super flu,\" in Bali. He stated that super flu is a common flu with a very low fatality rate.\"This flu routinely occurs because it has always been happening. But my friends can be more relaxed because the fatality rate is very low,\" said Budi when met at the Ministry of Health building in Jakarta on Thursday night, January 15, 2026.The two cases of super flu found in Bali were actually exposed to the virus since October 2025. The two survivors, aged between 40 and 50, experienced fever and shortness of breath. The Bali Health Office surveillance team then sent respiratory fluid samples to the Ministry of Health laboratory.","market":"fut","thumbnail":"https://statik.tempo.co/data/2025/10/27/id_1437419/1437419_720.jpg","type":0,"news_type":0,"thumbnails":["https://statik.tempo.co/data/2025/10/27/id_1437419/1437419_720.jpg"],"rights":{"source":"tempo_highlight","url":"https://en.tempo.co/read/2080773/health-minister-responds-to-reports-of-two-super-flu-cases-in-bali","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://en.tempo.co/read/2080773/health-minister-responds-to-reports-of-two-super-flu-cases-in-bali","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tempo_highlight","symbols":["CDC","BK4196","WGS"],"gpt_icon":0},{"id":"1176591322","title":"Stock Track | GeneDx Holdings Plummets 5.07% Intraday Amid Mixed Analyst Opinions","url":"https://stock-news.laohu8.com/highlight/detail?id=1176591322","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1176591322?lang=en_us&edition=fundamental","pubTime":"2026-01-13 23:10","pubTimestamp":1768317017,"startTime":"0","endTime":"0","summary":"GeneDx Holdings (WGS) saw its stock price drop sharply by 5.07% during intraday trading on Tuesday, reflecting investor concerns following mixed analyst opinions on the company.The healthcare sector,...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["WGS"],"gpt_icon":0},{"id":"2602954650","title":"GeneDx Shares Down 2.5% After Announcing Preliminary Q4 Results, 2026 Outlook","url":"https://stock-news.laohu8.com/highlight/detail?id=2602954650","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602954650?lang=en_us&edition=fundamental","pubTime":"2026-01-12 22:31","pubTimestamp":1768228298,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nFWN3YD0DR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4196","WGS"],"gpt_icon":0},{"id":"2602548585","title":"GeneDx Reports Preliminary Q4 Revenue; Issues 2026 Revenue Guidance","url":"https://stock-news.laohu8.com/highlight/detail?id=2602548585","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602548585?lang=en_us&edition=fundamental","pubTime":"2026-01-12 21:22","pubTimestamp":1768224171,"startTime":"0","endTime":"0","summary":"GeneDx  said Monday it expects fiscal Q4 revenue of $121 million.Analysts polled by FactSet expect $120.4 million.For full year 2025, the company said it expects total revenue of $427 million.Analysts surveyed by FactSet expect $427 million.The company also said it expects 2026 revenue of between $540 million and $555 million.Analysts polled by FactSet expect $529.2 million.GeneDx said it will report its Q4 results on Feb. 23 before the US market opens.Shares of the company were down 8.4% in recent Monday premarket activity.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4196","WGS"],"gpt_icon":0},{"id":"2602517158","title":"Genedx Holdings Corp. unveils presentation highlighting advances in rare disease diagnosis and genomics-driven healthcare","url":"https://stock-news.laohu8.com/highlight/detail?id=2602517158","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602517158?lang=en_us&edition=fundamental","pubTime":"2026-01-12 20:52","pubTimestamp":1768222322,"startTime":"0","endTime":"0","summary":"GeneDx Holdings Corp. presented at the J.P. Morgan 2026 Healthcare Conference, providing an overview of its current initiatives and advancements in rare disease diagnosis. The company highlighted its GeneDx Infinity platform, which comprises approximately one million exomes and genomes and over 2.5 million genetic tests, forming what it describes as the largest and most diverse rare disease dataset. The presentation detailed the use of proprietary AI models and algorithms to improve diagnostic accuracy, speed, and efficiency. GeneDx reported that more than 60% of its data includes parental information and over 50% represents individuals of non-European descent, supporting efforts to enhance diagnostic capabilities across populations. The company also outlined its collaborations with health systems, biopharma partners, advocacy groups, and policymakers to support patient care, accelerate drug discovery, and promote equitable access to genomic insights. You can access the full presentati","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nNDL9MFHh4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0070302665.USD","LU0417517546.SGD","LU2505996509.AUD","LU1116320737.USD","LU0203347892.USD","LU1032466523.USD","LU0256863811.USD","LU0310799852.SGD","LU2237443382.USD","LU2023250504.SGD","LU0787776722.HKD","WGS","LU2462157665.USD","LU0976567544.SGD","LU0211326755.USD","LU2023250330.USD","LU1261432733.SGD","LU1496350171.SGD","LU1496350502.SGD","IE00BN8TJ469.HKD","LU1917777945.USD","LU1280957306.USD","LU2106854487.HKD","LU0211327993.USD","LU0106831901.USD","LU2552382215.SGD","LU1366192091.USD","IE00BLSP4452.SGD","LU0640476718.USD","IE00BLSP4239.USD","LU0882574139.USD","LU1244550577.SGD","LU0345769128.USD","IE00BFXG1179.USD","LU0942090050.USD","LU1244550221.USD","LU2746668974.SGD","IE000M9KFDE8.USD","LU1974910355.USD","LU0238689110.USD","LU2505996681.GBP","LU0820561818.USD","LU2456880835.USD","IE00BJLML261.HKD","LU0345770993.USD","LU0251132253.USD","LU0265550946.USD","IE0034235303.USD","IE00BKVL7J92.USD","IE00B775SV38.USD"],"gpt_icon":0},{"id":"2602517205","title":"GeneDx reports preliminary Q4 revenue $121M, consensus $120.49M","url":"https://stock-news.laohu8.com/highlight/detail?id=2602517205","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602517205?lang=en_us&edition=fundamental","pubTime":"2026-01-12 20:50","pubTimestamp":1768222220,"startTime":"0","endTime":"0","summary":"Reports preliminary FY25 revenue $427M, consensus $427.04M. “In 2025, GeneDx (WGS) continued its journey of transforming the standard of pediatric ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/genedx-reports-preliminary-q4-revenue-121m-consensus-120-49m-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/genedx-reports-preliminary-q4-revenue-121m-consensus-120-49m-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["WGS","BK4196"],"gpt_icon":0},{"id":"2602249512","title":"GeneDx Projects 2026 Revenue of Up to $555 Million with Strong Exome and Genome Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2602249512","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602249512?lang=en_us&edition=fundamental","pubTime":"2026-01-12 20:31","pubTimestamp":1768221093,"startTime":"0","endTime":"0","summary":"GeneDx Holdings Corp. has announced its preliminary financial results for 2025 and shared its outlook for 2026. For the full year 2025, the company expects revenues of approximately $427 million, representing a 41% increase year-over-year. Exome and genome revenue is projected to grow by 54% for the year, or 58% when excluding a one-time benefit in 2024. Exome and genome volume growth is expected to exceed 30% for 2025, with the fourth quarter accelerating to 34.3%. The adjusted gross margin for both the full year and fourth quarter of 2025 is anticipated to be 71%. Looking ahead to 2026, GeneDx forecasts revenues between $540 million and $555 million, with exome and genome revenue and volume expected to grow by 33% to 35%. The company also expects an adjusted gross margin of at least 70% and positive adjusted net income for the year.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nNDL3zSYTM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4196","WGS"],"gpt_icon":0},{"id":"2602512118","title":"GeneDx Announces Preliminary 2025 Financial Results and Provides 2026 Guidance","url":"https://stock-news.laohu8.com/highlight/detail?id=2602512118","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602512118?lang=en_us&edition=fundamental","pubTime":"2026-01-12 20:30","pubTimestamp":1768221002,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nTUA83VNPF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4196","WGS"],"gpt_icon":0}],"profile":{"websiteUrl":"http://ir.genedx.com","stockEarnings":[{"period":"1week","weight":0.0695},{"period":"1month","weight":-0.1378},{"period":"3month","weight":-0.296},{"period":"6month","weight":-0.2866},{"period":"1year","weight":0.1558},{"period":"ytd","weight":-0.3069}],"compareEarnings":[{"period":"1week","weight":-0.0128},{"period":"1month","weight":-0.0125},{"period":"3month","weight":0.0146},{"period":"6month","weight":0.0595},{"period":"1year","weight":0.1181},{"period":"ytd","weight":-0.0002}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights. It also provides genetic diagnostic tests, screening solutions, and information with a focus on pediatrics, rare diseases for children and adults, and hereditary cancer screening. GeneDx Holdings Corp. is headquartered in Stamford, Connecticut.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.104041},{"month":2,"riseRate":0.833333,"avgChangeRate":0.370751},{"month":3,"riseRate":0.2,"avgChangeRate":-0.132973},{"month":4,"riseRate":0.2,"avgChangeRate":-0.003121},{"month":5,"riseRate":0.4,"avgChangeRate":-0.013957},{"month":6,"riseRate":0.6,"avgChangeRate":0.029191},{"month":7,"riseRate":0.8,"avgChangeRate":0.138059},{"month":8,"riseRate":0.2,"avgChangeRate":-0.136267},{"month":9,"riseRate":0.2,"avgChangeRate":-0.072401},{"month":10,"riseRate":0.8,"avgChangeRate":0.18872},{"month":11,"riseRate":0.2,"avgChangeRate":-0.130294},{"month":12,"riseRate":0.333333,"avgChangeRate":-0.04765}],"exchange":"NASDAQ","name":"GeneDx Holdings","nameEN":"GeneDx Holdings"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"GeneDx Holdings(WGS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest GeneDx Holdings(WGS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"GeneDx Holdings,WGS,GeneDx Holdings股票,GeneDx Holdings股票老虎,GeneDx Holdings股票老虎国际,GeneDx Holdings行情,GeneDx Holdings股票行情,GeneDx Holdings股价,GeneDx Holdings股市,GeneDx Holdings股票价格,GeneDx Holdings股票交易,GeneDx Holdings股票购买,GeneDx Holdings股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"GeneDx Holdings(WGS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest GeneDx Holdings(WGS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}